Clinicians Bladder Support Powder | 50g

Clinicians Bladder Support Powder

What is Bladder Support Powder?

Bladder Support is a pure powder form of D-mannose, a simple sugar that works rapidly to help combat bacterial infection causing chronic and recurrent urinary tract infection in women. Bladder Support promotes a healthy urinary tract and provides natural support for healthy bladder function.

Why use Bladder Support Powder?

Chronic and recurrent bladder infection is a very common problem for many women and long-term antibiotic treatment does not always resolve the problem. Bladder Support is a pure form of D-mannose, a simple sugar that works rapidly to help combat the bacteria that cause chronic and recurrent urinary tract infection in women. Bladder support promotes a healthy urinary tract and provides natural support for healthy bladder function.

What are the Key Benefits of Bladder Support Powder?

• Supports urinary tract health
• Promotes healthy bacterial balance in the urinary tract
• Pure D-mannose powder with no additives
• Pleasant taste, easy to use and fast-acting
• Suitable for daily use with flexible dosing
• Suitable for use during pregnancy and breastfeeding but following your doctor’s advice
• Does not contain sugar or artificial sweeteners
• Does not contain added colours, flavours, preservatives, gluten, or dairy

What causes urinary tract infection (UTI)?

Urinary tract infection UTI is caused by bacteria that originate in the intestines, travel up through the urethra (the tube that carries urine from the bladder to the outside of the body) and end up in the bladder, from where they may also go on to infect the kidneys. UTIs include cystitis, which is infection of the bladder causing increased frequency and urgency of urination, and pain or discomform with urination. Pyelonephritis is a more serious UTI caused by bacteria in the kidneys, with symptoms including fever, flank pain (pain in the upper abdomen, back and sides) and bacteriuria (bacteria in the urine). The bacteria that most commonly cause UTI, particularly cystitis, are Escherichia coli, (E. Coli) which normally inhabit the intestines without causing any problems (commensal relationship). However, when they become transferred to other locations such as the urinary tract, they develop specific organelles that allow them to bind and adhere to the epithelial cells of the urinary tract called uroepithelial cells. These uropathogenic E. Coli (UPEC) can then colonise a different habitat, which causes unpleasant symptoms for the host^{1, 2.}

How do uropathogenic E Coli cause recurrent UTI?

Before UPRC can colonise the bladder, the bacteria must be able to bind and adhere to the urothelial cells that line the urethra and the bladder. They do this using adhesive hair-like organelles called type 1 fimbriae (fim) or pilli, which are composed of subunits and tipped with the mannose-specific adhesin FimH. This adhesin FimH binds to protein receptors on the surface of urothelial cells, mainly glycoprotein uroplakin 1a that is rich in mannose residues^{3, 4.} Binding to the uroplakin receptor enables the bacteria to take hold, making it harder for the bacteria to be removed during urination so that they can replicate and colonise the bladder, resulting in sufficient numbers of bacterial cells (high viral load) that constitute an infection. Once attached to the surface of urothelial cells, the bacteria can also invade the cells and form a biofilm (a sticky matrix containing microorganisms), which can survive for long periods providing an ideal situation for recurrent infections, as it protects the bacteria from antibiotics and also from the host’s immune system^{5, 6, 7.}

What is recurrent UTI?

Recurrent UTI is defined as at least two UTIs in six months or three UTIs in one year and affects 20-30% of women with a UTI, which in itself is a common problem in women. A course of antibiotics may clear up the immediate infection but does not always prevent the infection from recurring, due to the perseverance of E. Coli colonies, as well as a build-up of antibiotic resistance, particularly when used for long-term for prophylaxis. Also, there are often unpleasant side effects associated with long-term antibiotic use. This has led to an interest in non-antibiotic treatments for recurrent UTI^{1, 7, 8, 9.}

What are the Ingredients of Bladder Support Powder?

Each dose (2 level spoons of powder) of Bladder Support contains the following ingredients:

D-Mannose 1500mg

D-Mannose

D-mannose is a natural simple monosaccharide sugar that is found in several fruits and vegetables, including cranberries, apples, blueberries, oranges, peaches, green beans and broccoli; it can also be extracted from larch rod for use in dietary supplements. It is closely related to glucose, but it is not metabolised to glycogen and, therefore, it is not stored in the body as an energy source. Also, D-mannose does not have any side effects on the body’s metabolism. Once ingested, D-mannose is rapidly absorbed and reaches the kidney within 30 minutes to be excreted via the urinary tract^{5, 9.}

How does D-mannose work to prevent recurrent UTI?

Animal studies and in vitro binding studies have demonstrated that D-mannose acts as a competitive inhibitor of bacterial binding and blocks the UPEC adhesion and invasion of uroepithelial cells. These studies indicated that D-mannose works by inhibiting the binding of E. Coli type 1 fimbriae to the mannose residues in the cell surface receptors of uroepithelial cells, so that the bacteria bind to free D-mannose in the urine instead and are then excreted. This reduces the viral load and also the risk of recurrent infection^{9, 10.}

Clinical studies

A clinical study comparing D-mannose treatment for recurrent UTI with the antibiotic nitrofurantoin found D-mannose to be equally effective in reducing the rate of recurrent UTI with reduced side effects^{11, 12.} These outcomes were supported by a further study using trimethoprim/sulfamethoxazole antibiotic combination^13. Based on the outcome of a study in which D-mannose reduced symptoms of UTI and risk of recurrence over a 6 month period, the use of D-mannose has been proposed as effective for non-antibiotic treatment, management and prophylaxis of recurrent UTI^9.

What are the Contraindications/Interactions of Bladder Support Powder?

You should always check the ingredients for known allergies and to ensure you do not have any allergies or sensitivities to these ingredients. Stop using if you develop any irritation or allergy while taking Bladder Support. Always read the label and use as directed or seek advice from your healthcare professional.
If you continue to have symptoms of UTI, you should consult your doctor.

Caution:

• Bladder Support is suitable to take while pregnant or breastfeeding, but you should consult your health professional before using.
• Side effects have been reported including loose stools, diarrhoea and bloating, but these are transitional and stop when you cease taking Bladder Support.
• It is important not to exceed the recommended dose, as prolonged high doses can be harmful to the kidneys.
• Although D-mannose is not metabolised and used as an energy source, you should consult your doctor before using Bladder Support if you are diabetic.

What are the Directions for using Bladder Support Powder?

Using the measuring spoon provided, measure the recommended amount of Bladder Support powder and dissolve in a glass of water. Swallow the contents of the glass and repeat every 3-4 hours during waking hours for 48 hours. Then take the reduced dose once or twice daily for 3 additional days.

Dosage:

Adults:

2 level 1.25ml measures for the first 48 hours
Half to 1 measure for the next 3 days

Children 4 years and over:

1 level 1.25ml measures for the first 48 hours
Quarter to half a measure for the next 3 days

Product Size

50g Powder

References

The following references provide scientific support for the use of this product:

1. Kodner CM, Gupton EK. Recurrent Urinary Tract Infections in Women: Diagnosis and Management. Am Fam Physician.2010 Sep 15;82(6):638-643.
2. Mobley HL, Donnenberg MS, Hagan EC. Uropathogenic Escherichia coli. EcoSal Plus.2009 Aug;3(2).
3. Zhou G, Mo W-J, Sebbel P, Min G, Neubert TA, et al. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding. Journal of Cell Science 2001 114: 4095-4103.
4. Kątnik-Prastowska I, Lis J, Matejuk A. Glycosylation of uroplakins. Implications for bladder physiopathology. Glycoconj J. 2014; 31(9): 623–636.
5. Rosen DA, Pinkener JS, Walker JN, Elam JS, Jones JM, Hultgren SJ. Molecular variations in Klebsiella pneumonia and Escherichia coli FimH affect function and pathogenesis in the urinary tract. Infect Immun 2008;76:3346-3356.
6. Terlizzi ME, Gribaudo G, Maffei ME. UroPathogenic Escherichia coli (UPEC) Infections: Virulence Factors, Bladder Responses, Antibiotic, and Non-antibiotic Antimicrobial Strategies. Microbiol.2017 Aug 15;8:1566.
7. Beerepoot M, Geerlings S. Non-Antibiotic Prophylaxis for Urinary Tract Infections. Pathogens. 2016 Jun; 5(2): 36.
8. Bergamin PA, Kiosoglous AJ. Non-surgical management of recurrent urinary tract infections in women. Transl Androl Urol 2017 Jul; 6(Suppl 2): S142–S152.
9. Domenici L, Monti M, Bracchi C, Giorgini M, Colagiovanni V, Muzii L, Benedetti Panici P. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci.2016 Jul;20(13):2920-5.
10. Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol.2005 Jan;55(2):441-55.
11. Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol.2014 Feb;32(1):79-84
12. https://www.ncbi.nlm.nih.gov/pubmed/23633128
13. Altarac S, Papeš D. Use of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int2014;113:9–10.
14. Porru D, Parmigiani A, Tinelli C, Barletta D, Choussos C, et al. Oral D-mannose in recurrent urinary tract infections in women: a pilot study. J Clin Urology 2014;7 (3) 208-213.